- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04812847
Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico (InfGNMDR-Neo)
Infecciones Por patógenos Gramnegativos Con Multirresistencia a Drogas en Neonatos de Alto Riesgo en el Noreste de México
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose a mixed design approach, a cohort´s study with a nested case-control analysis. Study subjects will be the gram-negative isolates at the study hospital clinical laboratory. The cohort´s exposure factor will be the presence or absence of a multidrug resistance gram-negative bacterial isolate.
The prospective cohort will allow the estimation of Gram-negative infection burden in the study population, and the characterization of all microorganisms isolates from study subjects at the phenotype and genotype level, specifically in relation to the expression of multi-drug resistance (MDR) associated genes (Molecular characterization of Gram-negative MDR isolates); the cohort will be formed by each neonate, from the admission to special care, the isolation date and then follow-up until the resolution, being it discharge either alive, dead or by transfer to another facility. Risk ratios for each of these outcomes will be calculated.
Cases-controls analysis will allow the research team to identify main risk factors present in those individuals who further had or did not have a gram-negative MDR isolate, by calculation of associated odds ratios for concurrent perinatal factors. Another project goal, to establish correlations and measure risk factors (Odds ratios) between Gram-negative infection with MDR organisms and concurrent illness and treatments offered in the special care nursery (medical [antibiotics, non-steroid anti-inflammatory drugs, steroids, others], surgical, and clinical procedures) in neonates under special care, will also be attained through the nested cases and controls study approach.
Finally, a derivative from this project will be the establishment of the North-East Mexico Regional Repository of bacterial isolates in Neonates under special care. At the first stage, this repository will preserve specimens of bacteria, both Gram-negative and Gram-positive, along with a specially developed anonymous database of the individuals hosting those infections. In the near future, the focus of this repository may expand to fungus, parasites and perhaps viral isolates preservation.
The research team has also proposed an exploratory objective, subject to budget availability, and that is the characterization and comparison of the immuno-phenotype of those individuals affected of Gram-negative infection with MDR resistant organisms, those with infection with other organisms and those not affected by infectious complications.
All gram-negative isolates will be probed for the gene expression of 38 selected antibiotic resistance loci, and 96 selected samples will be further studied by next generation sequentiation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Nuevo León
-
Ciudad Guadalupe, Nuevo León, Mexico, 67140
- Hospital Regional Materno Infantil de Alta Especialidad, Secretaría de Salud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Neonates of either sex, and any gestational age, admitted to the special care nursery of Hospital Regional Materno Infantil (Includes also out-born and transferred babies),
- Treating physician´s order to draw any biological sample and send it for culture at the hospital´s clinical laboratory.
- A culture with an isolate of Gram-negative bacteria.
Exclusion Criteria:
- Any culture negative for bacterial growth
- Any culture with Gram-positive bacteria, or fungus growth.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Gram negative infection, MDR present
Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
|
Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
|
Gram negative infection, MDR absent
Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
|
Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Burden of Gram Negative organisms infections
Time Frame: Through study completion, an average of three months
|
The isolation of a gram-negative organism, from any clinical site, in neonates under clinical care in special care nursery; Incidence = New cases during the study period, Prevalence = Total cases during the study period.
|
Through study completion, an average of three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Odds ratio for the occurrence of Gram-negative MDR infections
Time Frame: Through study completion, an average of three months
|
To identify and measure the Odds-ratio for the occurrence of Gram-negative infection with MDR resistant organisms and all concurrent perinatal factors.
This will be done through a nested case and controls study approach.
|
Through study completion, an average of three months
|
Risk factors for the occurrence of Gram-negative MDR infections.
Time Frame: Through study completion, an average of three months
|
To establish correlations and measure risk factors (Relative risks) between Gram-negative infection with MDR organisms and concurrent illness and treatments offered in the special care nursery (medical [antibiotics, non-steroid anti-inflammatory drugs, steroids, others], surgical, and clinical procedures) in neonates under special care.
This will be attained with a cohorts study approach.
|
Through study completion, an average of three months
|
Collaborators and Investigators
Investigators
- Study Chair: Victor Javier Lara-Diaz, MD, PhD, Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud
- Principal Investigator: Cuauhtémoc Licona-Cassani, PhD, Tecnológico de Monterrey, Centro de Biotecnología FEMSA
- Principal Investigator: Marion Genevieve Brunck, PhD, Tecnológico de Monterrey, Escuela de Ingeniería y Ciencias, GIEE on Translational Omics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- InfGNMDR-Neo
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant Newborn Disease
-
Centre Hospitalier Universitaire de Saint EtienneCompletedInfant, Newborn, DiseaseFrance
-
King's College LondonKing's College Hospital NHS TrustCompletedInfant, Newborn, DiseaseUnited Kingdom
-
Çanakkale Onsekiz Mart UniversityCompletedPosition | Comfort | Newborn, Infant, Disease | ResidualTurkey
-
Lithuanian University of Health SciencesResearch Council of LithuaniaCompletedNewborn, Infant, Disease | Peri-operative InjuryLithuania
-
Turku University HospitalUniversity of TurkuCompletedParent-Child Relations | Parenting | Infant, Newborn, Disease
-
Neosense TechnologiesTerminatedNewborn, Infant, Disease | Oxygen Saturation | CathetersSweden
-
Jerry Vockley, MD, PhDEnrolling by invitationGenetic Disease | Infant, Newborn, DiseaseUnited States
-
Saglik Bilimleri UniversitesiPendik District Health DirectorateCompletedPain | Infant, Newborn, DiseaseTurkey
-
Sharp HealthCareFood and Drug Administration (FDA)CompletedInfant, Newborn, DiseaseUnited States
-
Policlinico Universitario, CataniaRecruitingNewborn Morbidity | Premature Infant DiseaseItaly
Clinical Trials on Identification of MDR characteristics
-
CHU de ReimsRecruitingMultidrug ResistanceFrance
-
Region SkaneLund UniversityNot yet recruitingMulti-antibiotic Resistance
-
EDUARDO ALBENIZInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Fundació... and other collaboratorsRecruitingGastric Cancer | Gastric Neoplasms | Gastric LesionSpain
-
Hospices Civils de LyonCompleted
-
AZ NikolaasCompleted
-
Poitiers University HospitalActive, not recruiting
-
Methodist Health SystemCompletedNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisUnited States
-
Institut Paoli-CalmettesUnknown
-
University Hospital, MontpellierUnknownBalanced Chromosomal TranslocationFrance
-
University of Sao PauloCompletedAging | Accidental FallsBrazil